Anticoagulating Budd–Chiari syndrome patients presenting with variceal bleed: A retrospective study

Background and Aim This aims to study incidence of re‐bleeding on anticoagulation and survival of Budd–Chiari syndrome (BCS) patients presenting with variceal bleeding. Methods Budd–Chiari syndrome patients presenting with variceal bleed between 01/01/2007 and 01/05/2019 were retrospectively studied...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2020-08, Vol.35 (8), p.1397-1403
Main Authors: Sharma, Anand, Goel, Ashish, Moses, Vinu, Keshava, Shyamkumar Nidugala, Zachariah, Uday George, Elias, Elwyn, Eapen, Chundamannil Eapen
Format: Article
Language:English
Subjects:
Angioplasty
anticoagulation
Ascites
Bleeding
Budd–Chiari syndrome
Cardiovascular system
Endoscopy
Hepatic vein
hepatic vein thrombosis
hepatology
Implants
Liver
Survival
variceal bleed
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim This aims to study incidence of re‐bleeding on anticoagulation and survival of Budd–Chiari syndrome (BCS) patients presenting with variceal bleeding. Methods Budd–Chiari syndrome patients presenting with variceal bleed between 01/01/2007 and 01/05/2019 were retrospectively studied. Patients underwent endoscopic treatment ± endovascular therapy, followed by anticoagulation. Variceal re‐bleed (on anticoagulation) and survival were studied. Results Of 376 BCS patients diagnosed during the study period, 40 (10.7%) patients, presenting with variceal bleed (age 33 [25–40] years; male patients 70%; Rotterdam score 1.13 [0.63–1.22]), Group 1 were compared with 40 randomly selected age‐matched BCS patients presenting with ascites, no bleeds (40 [23–42] years; male patients 42.5%; Rotterdam score 1.11 [1.09–1.16]), Group 2. The commonest site of obstruction was hepatic vein (65%) in Group 1 and combined hepatic veins and inferior vena cava (57.5%) in Group 2 (P 
ISSN:0815-9319
1440-1746
DOI:10.1111/jgh.14971